MX364535B - Antígenos asociados con enfermedad inflamatoria del intestino. - Google Patents

Antígenos asociados con enfermedad inflamatoria del intestino.

Info

Publication number
MX364535B
MX364535B MX2015003908A MX2015003908A MX364535B MX 364535 B MX364535 B MX 364535B MX 2015003908 A MX2015003908 A MX 2015003908A MX 2015003908 A MX2015003908 A MX 2015003908A MX 364535 B MX364535 B MX 364535B
Authority
MX
Mexico
Prior art keywords
bowel disease
inflammatory bowel
antigens associated
specific binding
conjugated
Prior art date
Application number
MX2015003908A
Other languages
English (en)
Other versions
MX2015003908A (es
Inventor
Denise O'hara
Giovanni Neri
Kathrin Schwager
Melanie Ruzek
Jianqing Chen
Original Assignee
Philogen Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50435280&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX364535(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Philogen Spa filed Critical Philogen Spa
Publication of MX2015003908A publication Critical patent/MX2015003908A/es
Publication of MX364535B publication Critical patent/MX364535B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2066—IL-10
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6843—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/626—Diabody or triabody

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere a miembros de unión específicos que se unen a la isoforma del ED-A de la fibronectina, para usarse en métodos de tratamiento, diagnóstico, detección y/o formación de imágenes de enfermedad inflamatoria del intestino (IBD), y/o para usarse en el suministro hacia el tejido con IBD, de una molécula conjugada con el miembro de unión específico; el miembro de unión específico puede ser conjugado, por ejemplo, con una molécula inmunosupresora o antiinflamatoria, tal como interleucina-10.
MX2015003908A 2012-10-03 2012-10-03 Antígenos asociados con enfermedad inflamatoria del intestino. MX364535B (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2012/058574 WO2014055073A1 (en) 2012-10-03 2012-10-03 Antigens associated with inflammatory bowel disease

Publications (2)

Publication Number Publication Date
MX2015003908A MX2015003908A (es) 2015-08-05
MX364535B true MX364535B (es) 2019-04-29

Family

ID=50435280

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015003908A MX364535B (es) 2012-10-03 2012-10-03 Antígenos asociados con enfermedad inflamatoria del intestino.

Country Status (22)

Country Link
US (2) US9695232B2 (es)
EP (1) EP2903629B1 (es)
JP (1) JP6158933B2 (es)
KR (1) KR102011549B1 (es)
CN (2) CN104768563B (es)
AU (1) AU2012391490B2 (es)
CA (1) CA2886152C (es)
CO (1) CO7380754A2 (es)
DK (1) DK2903629T3 (es)
ES (1) ES2743423T3 (es)
HK (1) HK1212220A1 (es)
HU (1) HUE044927T2 (es)
IL (1) IL237856B (es)
IN (1) IN2015DN03229A (es)
MX (1) MX364535B (es)
PH (1) PH12015500662B1 (es)
PL (1) PL2903629T3 (es)
PT (1) PT2903629T (es)
RU (1) RU2612878C2 (es)
SG (1) SG11201502404WA (es)
SI (1) SI2903629T1 (es)
WO (1) WO2014055073A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2010004726A (es) 2007-10-30 2010-05-20 Philogen Spa Antigeno asociado con artritis reumatoide.
HUE044927T2 (hu) 2012-10-03 2019-11-28 Philogen Spa Ellenanyag-konjugátum, gyulladásos bélbetegség kezelésében történõ alkalmazásra
GB201507908D0 (en) 2015-05-08 2015-06-24 Philogen Spa IL2 and TNF immunoconjugates
US20190309060A1 (en) 2016-01-15 2019-10-10 Philogen S.P.A. Intestinal antigens for pharmacodelivery applications
CA3065153C (en) * 2017-06-07 2023-09-05 Philogen S.P.A. Vascular endothelial growth factor/anti-fibronectin antibody fusion proteins
KR20210139312A (ko) * 2019-03-06 2021-11-22 데카 바이오사이언시즈, 인크. Il-10 변이체 분자, 및 염증 질환 및 종양학의 치료 방법
WO2020249757A1 (en) 2019-06-14 2020-12-17 Philogen S.P.A Immunoconjugates comprising a single chain diabody and interleukin-15 or interleukin-15 and a sushi domain of interleukin-15 receptor alpha
EP4185615A1 (en) 2020-07-22 2023-05-31 Philogen S.p.A. Treatment of pulmonary hypertension
WO2023175077A1 (en) 2022-03-17 2023-09-21 Philogen S.P.A Anti-ed-a antibodies for the treatment of pulmonary hypertension

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE425839C (de) 1923-08-09 1926-03-02 Optische Anstalt C P Goerz Akt Verfahren zur Erzeugung des Schleifdruckes und der Schleifrelativbewegung zwischen dem Gegenstande, dessen Oberflaeche durch Schleifen bearbeitet werden soll (Glas, Linse usw.), und der Schleifflaeche des umlaufenden Schleifwerkzeuges
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
IT1217724B (it) 1988-05-26 1990-03-30 Ist Naz Ric Sul Cancro Anticorpo monoclonale specifico per una sequenza di fibronettina espressa in cellule trasformate ibridoma secernente tale anticorpo e impiego dell'anticorpo monoclonale per la diagnosi di tumori
US5420012A (en) 1989-05-08 1995-05-30 Locus Genex Oy Method for the detection of reactive conditions
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
GB9206318D0 (en) 1992-03-24 1992-05-06 Cambridge Antibody Tech Binding substances
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
WO1992017604A1 (en) 1991-03-26 1992-10-15 Otsuka Pharmaceutical Factory, Inc. Anti-eda monoclonal antibody
US5858657A (en) 1992-05-15 1999-01-12 Medical Research Council Methods for producing members of specific binding pairs
US6492160B1 (en) 1991-05-15 2002-12-10 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
US5871907A (en) 1991-05-15 1999-02-16 Medical Research Council Methods for producing members of specific binding pairs
US6225447B1 (en) 1991-05-15 2001-05-01 Cambridge Antibody Technology Ltd. Methods for producing members of specific binding pairs
US5962255A (en) 1992-03-24 1999-10-05 Cambridge Antibody Technology Limited Methods for producing recombinant vectors
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
JPH07501451A (ja) 1991-11-25 1995-02-16 エンゾン・インコーポレイテッド 多価抗原結合タンパク質
ES2227512T3 (es) 1991-12-02 2005-04-01 Medical Research Council Produccion de anticuerpos contra auto-antigenos a partir de repertorios de segmentos de anticuerpos fijados en un fago.
US5872215A (en) 1991-12-02 1999-02-16 Medical Research Council Specific binding members, materials and methods
US5932214A (en) * 1994-08-11 1999-08-03 Biogen, Inc. Treatment for inflammatory bowel disease with VLA-4 blockers
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
US5368854A (en) * 1992-08-20 1994-11-29 Schering Corporation Use of IL-10 to treat inflammatory bowel disease
AU690528B2 (en) 1992-12-04 1998-04-30 Medical Research Council Multivalent and multispecific binding proteins, their manufacture and use
US5644033A (en) 1992-12-22 1997-07-01 Health Research, Inc. Monoclonal antibodies that define a unique antigen of human B cell antigen receptor complex and methods of using same for diagnosis and treatment
US6054312A (en) 1997-08-29 2000-04-25 Selective Genetics, Inc. Receptor-mediated gene delivery using bacteriophage vectors
CA2351346C (en) 1998-12-10 2015-09-01 Phylos, Inc. Protein scaffolds for antibody mimics and other binding proteins
PT1257297E (pt) 2000-02-24 2006-12-29 Philogen Spa Composições e método para tratamento da angiogénese em lesões patológicas
WO2001076630A1 (fr) 2000-04-06 2001-10-18 Kyowa Hakko Kogyo Co., Ltd. Diagnostics et remedes contre la polyarthrite rhumatoide
WO2001083816A2 (en) 2000-05-04 2001-11-08 Philogen S.R.L. Method for detecting tumors
JP2004529848A (ja) 2000-09-07 2004-09-30 シエーリング アクチエンゲゼルシャフト ＥＤｂ−フィブロネクチンドメイン（ＩＩ）の受容体
US6780594B2 (en) 2000-09-25 2004-08-24 Schering Aktiengesellschaft Method for in vitro diagnosis of endometriosis
IT1317108B1 (it) 2000-12-06 2003-05-26 Philogen Srl Processo per la selezione di frammenti anticorporali anti-angiogenesi,frammenti anticorpali anti-angiogenesi cosi' ottenuti e loro uso.
US20020187100A1 (en) 2000-12-21 2002-12-12 David Rizzieri Anti-tenascin monoclonal antibody therapy for lymphoma
EP1224943A1 (en) 2001-01-19 2002-07-24 Crucell Holland B.V. Fibronectin as a tumor marker detected by phage antibodies
GB0209896D0 (en) 2002-04-30 2002-06-05 Molmed Spa Conjugate
AU2003238284A1 (en) 2002-06-21 2004-01-06 Duke University Anti-tenascin antibody fragments and minibodies for treatment of lymphoma
CN101972478B (zh) 2002-10-08 2012-10-31 免疫医疗公司 抗体治疗
EP1572242B1 (en) 2002-12-13 2014-04-16 Immunomedics, Inc. Immunoconjugates with an intracellularly-cleavable linkage
US20040202666A1 (en) 2003-01-24 2004-10-14 Immunomedics, Inc. Anti-cancer anthracycline drug-antibody conjugates
US7560095B2 (en) 2003-04-22 2009-07-14 A & G Pharmaceutical, Inc. Cancer specific monoclonal antibodies
WO2005009366A2 (en) 2003-07-24 2005-02-03 Cornell Research Foundation, Inc. Restoring vascular function
WO2005086612A2 (en) 2003-07-29 2005-09-22 Immunomedics, Inc. Fluorinated carbohydrate conjugates
US8048432B2 (en) 2003-08-06 2011-11-01 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Polysaccharide-protein conjugate vaccines
CA2552590A1 (en) 2004-01-05 2005-07-21 Emd Lexigen Research Center Corp. Interleukin-12 targeted to oncofoetal fibronectin
ATE534750T1 (de) 2004-07-30 2011-12-15 Adeza Biomedical Corp Onkofetales fibronektin als zervixkarzinom-marker
US7785591B2 (en) 2004-10-14 2010-08-31 Morphosys Ag Identification and characterization of function-blocking anti-ED-B-fibronectin antibodies
JP2008518609A (ja) 2004-11-09 2008-06-05 フィロゲン エスピーエー テネイシンｃに対する抗体
EP1831254B1 (en) 2004-12-23 2012-06-06 Molmed SpA Conjugation product
ATE459648T1 (de) 2005-05-11 2010-03-15 Philogen Spa Fusionsprotein von antikörper l19 gegen fibronectin ed-b und interleukin 12
CA2612186A1 (en) 2005-06-23 2007-01-04 Emory University Imaging agents
CN103145838A (zh) * 2005-06-30 2013-06-12 Abbvie公司 Il-12/p40结合蛋白
EP2015775B1 (en) 2006-05-03 2011-06-01 Bayer Schering Pharma Aktiengesellschaft Combination of an anti edb fibronectin domain antibody l19-sip and an anti-egfr antibody
CA2648484A1 (en) 2006-05-08 2007-11-15 Philogen Spa Antibody-targeted cytokines for therapy
AU2008234615B2 (en) 2007-04-02 2013-10-10 Philogen S.P.A. The ED-A antigen of fibrinogen is associated with the neovasculature of tumour metastases
WO2009013619A2 (en) 2007-07-25 2009-01-29 Philogen S.P.A The ed-a antigen of fibrinogen is associated with the neovas culature of tumor metastases
MX2010004726A (es) 2007-10-30 2010-05-20 Philogen Spa Antigeno asociado con artritis reumatoide.
US20110318302A1 (en) 2009-01-07 2011-12-29 Kathrin Schwager Cancer Treatment
EP2379116B1 (en) 2009-01-07 2015-08-26 Philogen S.p.A. Antigens associated with endometriosis
EP2461832B1 (en) 2009-08-05 2017-06-28 Philogen S.p.A. Targeting of bone marrow neovasculature
AU2011307236A1 (en) 2010-09-29 2013-03-28 Philogen S.P.A. Thiazolidine linker for the conjugation of drugs to antibodies
EP3834847A1 (en) 2011-07-27 2021-06-16 Philogen S.p.A. Il-12 immunoconjugate
HUE044927T2 (hu) 2012-10-03 2019-11-28 Philogen Spa Ellenanyag-konjugátum, gyulladásos bélbetegség kezelésében történõ alkalmazásra
EP2988784A1 (en) 2013-04-25 2016-03-02 Philogen S.p.A. Antibody-drug conjugates
EP2988826A1 (en) 2013-04-26 2016-03-02 Philogen S.p.A. Il4 conjugated to antibodies against extracellular matrix components
US9209965B2 (en) 2014-01-14 2015-12-08 Microsemi Semiconductor Ulc Network interface with clock recovery module on line card

Also Published As

Publication number Publication date
KR20150061648A (ko) 2015-06-04
ES2743423T3 (es) 2020-02-19
CN104768563B (zh) 2020-02-28
CO7380754A2 (es) 2015-09-10
US9695232B2 (en) 2017-07-04
DK2903629T3 (da) 2019-08-05
CA2886152A1 (en) 2014-04-10
KR102011549B1 (ko) 2019-08-16
MX2015003908A (es) 2015-08-05
PL2903629T3 (pl) 2019-12-31
CA2886152C (en) 2020-01-14
EP2903629A1 (en) 2015-08-12
IN2015DN03229A (es) 2015-10-02
US10239939B2 (en) 2019-03-26
HUE044927T2 (hu) 2019-11-28
RU2612878C2 (ru) 2017-03-13
US20150361161A1 (en) 2015-12-17
AU2012391490A1 (en) 2015-04-30
US20180044408A1 (en) 2018-02-15
CN111329994A (zh) 2020-06-26
IL237856B (en) 2019-11-28
IL237856A0 (en) 2015-05-31
NZ631476A (en) 2017-06-30
PT2903629T (pt) 2019-09-10
SI2903629T1 (sl) 2019-09-30
PH12015500662A1 (en) 2015-05-18
PH12015500662B1 (en) 2015-05-18
CN104768563A (zh) 2015-07-08
SG11201502404WA (en) 2015-05-28
EP2903629A4 (en) 2016-07-27
JP6158933B2 (ja) 2017-07-05
RU2015115399A (ru) 2016-11-27
WO2014055073A1 (en) 2014-04-10
AU2012391490B2 (en) 2018-02-15
EP2903629B1 (en) 2019-07-10
HK1212220A1 (en) 2016-06-10
JP2016500670A (ja) 2016-01-14

Similar Documents

Publication Publication Date Title
PH12015500662A1 (en) Antigens associated with inflammatory bowel disease
EA201400579A1 (ru) Антитела к il-36r
EA032986B1 (ru) Пирролобензодиазепины
MX2019000225A (es) Composiciones y metodos para el tratamiento de enfermedades autoinmunes y otras enfermedades.
EP2590671A4 (en) IMMUNOGLOBULINS WITH DOUBLE VARIABLE DOMAIN AND USES THEREOF
MX2014000054A (es) Moleculas de union anti-alfa sinucleina.
EA201291039A1 (ru) Антитела, связывающие cd27 человека, и их применение
MX340295B (es) Anticuerpos monoclonales anti-c-met.
MX2015016111A (es) Anticuerpos anti-b7-h5 y sus usos.
MX2019000046A (es) Anticuerpos anti-il-23.
MX2013004979A (es) Inmunoglobulinas de dominio variable doble y usos de las mismas.
MX2013002270A (es) Inmonoglubinas de dominio variable doble y usos de las mismas.
TW201206473A (en) Dual variable domain immunoglobulins and uses thereof
MX2014008102A (es) Inmunoglobulinas de dominio variable dual contra receptores.
PH12014502406A1 (en) Anti-il-23p19 antibodies
MY163368A (en) Il-1-alpha and -beta bispecific dual variable domain immunoglobulins and their use
MX2015013166A (es) Proteinas de union especificas duales dirigidas contra il-1 beta y/o il-17.
MX365403B (es) Peptidos y metodos para usarlos.
PH12018500131A1 (en) Il22 immunoconjugates
MX356163B (es) Anilinas sustituidas como antagonistas de ccr(4).
IN2014DN06662A (es)
FR2979346B1 (fr) Nanocorps anti-vcam-1
BR112014032733A2 (pt) aparelho e métodos para a coleta de fardos
MY178558A (en) Antigens associated with inflammatory bowel disease
MX2012012509A (es) Tapentadol para usarse en el tratamiento del sindrome del intestino irritable.

Legal Events

Date Code Title Description
HH Correction or change in general
FG Grant or registration